COMPOSITION FOR PREVENTING OR TREATING ORAL DISEASES

Abstract

The present disclosure pertains to a composition for preventing or treating oral diseases. A composition for preventing or treating oral diseases according to an embodiment of the present disclosure can not only effectively prevent or treat tooth decay or periodontitis by inhibiting bacterial activity in the oral cavity but can also be used for a long period of time due to being non-toxic to human, and can be used in various formulations, such as oral tablets, toothpastes, gargles, and oral patches.

Claims

1. A composition for preventing or treating oral diseases, wherein the composition includes 1,2,3-butanetriol.

2. The composition according to claim 1, wherein the 1,2,3-butanetriol includes at least one selected from the group consisting of (2S, 3S) 1,2,3-butanetriol, (2S, 3R) 1,2,3-butanetriol, (2R, 3S) 1,2,3-butanetriol, and (2R, 3R) 1,2,3-butanetriol.

3. The composition according to claim 1, wherein the 1,2,3-butanetriol is included in a concentration of 0.001 wt. % to 0.250 wt. %.

4. The composition according to claim 1, further including an Ajiwain (Trachyspermum ammi) extract.

5. The composition according to claim 4, wherein the Ajiwain extract is extracted using one or more solvents selected from the group consisting of water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, diethyl ether, and cyclohexane from Ajiwain.

6. The composition according to claim 4, wherein the Ajiwain extract is extracted and concentrated in a ratio of 10:1 to 500:1, and wherein the Ajiwain extract is included at a concentration of 0.1 wt. % to 1 wt. %.

7. The composition according to claim 1, further including one or more additives selected from the group consisting of a water-soluble zinc salt, B vitamins, vitamin C, and vitamin E.

8. The composition according to claim 7, wherein the additive is included in a concentration of 0.001 wt. % to 10 wt. %.

9. The composition according to claim 1, wherein the composition has antibacterial activity against one or more types of bacteria selected from the group consisting of Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Treponema denticola, Prevotella nigrescens, Eubacterium nodatum, Parvimonas micra, Eikenella corrodens, Campylobacter rectus, Fusobacterium nucleatum (ATCC 25586), Streptococcus sobrinus, Streptococcus salivarius (GTCO215), Streptococcus anginasus (FW73), Streptococcus mutans (JCM5705), Prevotella intermedia (ATCC 25611), and Porphyromonas gingivalis (W83, ATCC 33277 (F), FDC 381).

10. The composition according to claim 1, wherein the composition has one or more formulations selected from the group consisting of toothpastes, mouthwashes, oral tablets, gums, candies, oral spray, oral ointment, oral varnish, and oral patches.

11. A method for preventing or treating oral diseases comprising: administering a composition of claim 1.

12. The method according to claim 11, wherein the 1,2,3-butanetriol is selected from the group consisting of (2S, 3S) 1,2,3-butanetriol, (2S, 3R) 1,2,3-butanetriol, (2R, 3S) 1,2,3-butanetriol, and (2R, 3R) 1,2,3-butanetriol.

13. The method according to claim 11, wherein the 1,2,3-butanetriol is included in a concentration of 0.001 wt. % to 0.250 wt. % of the total composition.

14. The method according to claim 11, further including an Ajiwain (Trachyspermum ammi) extract.

15. The method according to claim 14, wherein the Ajiwain extract is extracted using one or more solvents selected from the group consisting of water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, diethyl ether, and cyclohexane from Ajiwain.

16. The method according to claim 14, wherein the Ajiwain extract is extracted and concentrated in a ratio of 10:1 to 500:1, and wherein the Ajiwain extract is included at a concentration of 0.1 wt. % to 1 wt. %.

17. The method according to claim 11, further including one or more additives selected from the group consisting of a water-soluble zinc salt, B vitamins, vitamin C, and vitamin E.

18. The method according to claim 17, wherein the additive is included in a concentration of 0.001 wt. % to 10 wt. %.

19. The method according to claim 11, wherein the composition has antibacterial activity against one or more types of bacteria selected from the group consisting of Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Treponema denticola, Prevotella nigrescens, Eubacterium nodatum, Parvimonas micra, Eikenella corrodens, Campylobacter rectus, Fusobacterium nucleatum (ATCC 25586), Streptococcus sobrinus, Streptococcus salivarius (GTCO215), Streptococcus anginasus (FW73), Streptococcus mutans (JCM5705), Prevotella intermedia (ATCC 25611), and Porphyromonas gingivalis (W83, ATCC 33277 (F), FDC 381).

20. The method according to claim 11, wherein the composition has one or more formulations selected from the group consisting of toothpastes, mouthwashes, oral tablets, gums, candies, oral spray, oral ointment, oral varnish, and oral patches.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0066] FIG. 1 is a graph illustrating the culture viability of human fibroblasts according to the concentration change of 1, 2,3-butanetriol.

[0067] FIGS. 2 and 3 are graphs illustrating the activity inhibitory effect of 1,2,3-butanetriol on oral bacteria.

[0068] FIG. 4 is a graph illustrating the activity inhibitory effect of 1,2,3-butanetriol and Ajiwain extract on oral bacteria.

DETAILED DESCRIPTION OF THE INVENTION

[0069] Hereinafter, functions and effects of the present disclosure will be described in detail by specific examples of the present disclosure. Meanwhile, the examples are provided only to illustrate the present disclosure, and the scope of the invention is not limited thereto.

Examples

[0070] 1,2,3-butanetriol was used by purchasing a commercially available racemic mixture of optical isomers. (product of Sigma-Aldrich)

[0071] The Ajiwain extract was used as an extract obtained by extracting the seeds and leaves of Ajiwain (Trachyspermum ammi) in a ratio of about 20:1 using water.

[0072] Cytotoxicity Test

[0073] First, to examine the biotoxicity of 1,2,3-butanetriol, culture survival experiments of human fibroblasts according to the concentration change of 1,2,3-butanetriol were conducted.

[0074] The initial seeding density was 5000 cells/well based on 96 wells, and the culture conditions were as follows:

[0075] Dulbecco's Modified Eagle Medium (DMEM)+Fetal Bovine Serum (FBS) 10%; 37° C., 5% CO.sub.2; and 12 hours after seeding, 1,2,3-butanetriol was treated at different concentrations to determine cytotoxicity, and after 48 hours of 1,2,3-butanetriol treatment, Dojindo Cell Counting Kit-8 was dispensed at a rate of 10 μl per well and incubated at 37° C. for 2 hours, then cell viability was measured at 450 nm Absorbance.

[0076] The measurement results are shown in FIG. 1.

[0077] FIG. 1 is a graph illustrating the culture viability of human fibroblasts according to the concentration change of 1, 2,3-butanetriol, and the horizontal axis of FIG. 1 indicates the concentration of the treated 1,2,3-butanetriol in an mM unit.

[0078] Referring to FIG. 1, it was identified that the cell viability as not significantly reduced at a concentration of about 12.5 mM or less, and the cell viability is about 50% at a concentration of about 25 mM.

[0079] Antibacterial test: 1,2,3-butanetriol

[0080] Subsequently, to examine the effect of inhibiting bacterial activity in plaque, bacterial strains were prepared as follows.

[0081] First, plaque was collected from three research participants, and was cultured in a BHI medium (Bovine Heart Infusion 4 g/160 ml distilled water-DDW) with 1 wt. % sucrose added for 24 hours.

[0082] From the above cultured strain, gDNA was extracted, and the bacteria were identified through PCR.

[0083] The identified bacterial species are shown in Table 1 below.

TABLE-US-00001 TABLE 1 Bacterial species Abbreviations Aggregatibacter actinomycetemcomitans Aa Porphyromonas gingivalis Pg Tannerella forsythia Tf Treponema denticola Td Fusobacterium nucleatum Fn Prevotella nigrescens Pn Streptococcus mutans Sm Prevotella intermedia Pi Eubacterium nodatum En Parvimonas micra Pm Eikenella corrodens Ec Total bacterial load Tb Campylobacter rectus Cr Streptococcus sobrinus Ss

[0084] BHI medium (Bovine Heart Infusion 4 g/160 ml distilled water-DDW) with 1wt. % sucrose added was prepared and sterilized in a high-temperature and high-pressure autoclave. Then, 1,2, 3-butanetriol (1,2,3-BT) was dispensed to each concentration, and a 96-well microplate containing 180 μl of the culture solution was prepared.

[0085] Here, 20 μl of the culture solution in which the bacteria in plaque prepared above was proliferated was dispensed per well.

[0086] This microplate was placed in a Biotek Synergy 2 microplate reader, the temperature was adjusted to 37° C., and the absorption rate was measured at 600 nm.

[0087] The measurement results are shown in FIG. 2.

[0088] Separately from the absorption rate measurement, gDNA was extracted from the well microplate after treatment with butanetriol, and the results identified by PCR are shown in FIG. 3.

[0089] FIGS. 2 and 3 are graphs illustrating the activity inhibitory effect of 1,2,3-butanetriol on oral bacteria.

[0090] Referring to FIG. 2, it was identified that when 1,2, 3-butanetriol is treated, bacterial growth was significantly effectively inhibited. It was clearly identified that when 12 hours have elapsed after culturing, an effect of inhibiting bacterial growth of at least about 10% or more, and a maximum of about 50% or more was exhibited, compared to the case in which the 1,2,3-butanetriol is not treated. Referring to FIG. 3, the growth inhibitory effect of 1,2,3-butanetriol on each bacterial species was clearly identified.

[0091] Antibacterial test: 1,2,3-butanetriol+Ajiwain extract

[0092] To identify the synergistic effect produced when an Ajiwain extract is used, BHI medium (Bovine Heart Infusion 4 g/160 ml distilled water-DDW) with 1 wt. % sucrose added was prepared and sterilized. Then, 1,2,3-butanetriol (1,2,3-BT) and Ajiwain extract were dispensed to each concentration, and a 96-well microplate containing 180 μl of the culture solution was prepared.

[0093] 1,2,3-Butanetriol concentration: 0.66 mg/ml

[0094] Ajiwain extract concentration: AZ0.05:0.05 mg/ml; AZ0.5:0.5 mg/ml

[0095] Here, 20 μl of the culture solution in which the bacteria in plaque prepared above was proliferated was dispensed per well.

[0096] This microplate was placed in a Biotek Synergy 2 microplate reader, the temperature was adjusted to 37° C., and the absorption rate was measured at 600 nm.

[0097] The measurement results are shown in FIG. 4.

[0098] Referring to FIG. 4, compared to the case where only 1,2,3-butanetriol was treated alone, when 1,2,3-butanetriol and Ajiwain extract were simultaneously treated, it was clearly identified that the effect of inhibiting bacterial growth was greatly increased. When the Ajiwain extract was used in high concentration (AZ50+BT), it was identified that it exhibited about 80% effect of inhibiting bacterial growth compared to the case without any treatment (CON).